Skip to content

Safety and effectiveness analysis of interventional therapy for peripheral deep venous thrombosis of lower extremities

Safety and effectiveness analysis of interventional therapy for peripheral deep venous thrombosis of lower extremities

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092262
Enrollment
Unknown
Registered
2024-11-13
Start date
2024-08-15
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep venous thrombosis of lower extremity

Interventions

Interventional therapy group:Received endovascular interventional therapy, including contact catheter thrombolysis and mechanical thrombolysis.

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It met the diagnostic criteria for DVT of lower limbs, and was diagnosed as peripheral type by ultrasound or contrast of deep veins of lower limbs; (2) Onset time 12 months; (3) Age 18-75 years old; (4) Unilateral disease; (5) Complete clinical data; (6) Agree to join the group and sign a written informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe iliac vein stenosis; (2) Pulmonary embolism, skin and mucous membrane bleeding, hematuria and hematochezia were present before operation; (3) There are absolute contraindications of thrombolysis (such as cerebrovascular events within 2 months, gastrointestinal bleeding within 10 days, active bleeding focus, history of cranial surgery within 3 months, etc.) and relative contraindications (such as: Hypertension, difficult compression of the vascular puncture site, history of recent eye surgery, intracranial tumors, non-vascular major surgery within 10 days, history of cardiopulmonary resuscitation, etc.) or other contraindications (such as: contrast media allergy, abnormal coagulation function, bacterial endocarditis, liver failure, pregnant or lactating women, renal insufficiency, active glyuria proliferative retinopathy, etc.); (4) thrombotic constitution, that is, there are antithrombin, protein C or S defects, clotting factor V Leiden mutation, prothrombin G20210A mutation, antiphospholipid syndrome; (5) Patients who cannot tolerate surgery; (6) Pregnant and lactating patients.

Design outcomes

Secondary

MeasureTime frame
General medical records (age, sex, past history, personal history, etc.); Lesion characteristics (lesion site, diseased limb, clinical symptoms and signs, circumference of affected limb, etc.);

Primary

MeasureTime frame
Circumference of affected limb, AVVQ score, Villalta score, incidence of pulmonary embolism, bleeding event, incidence of thrombosis spread, cardio-cerebrovascular disease;

Countries

China

Contacts

Public ContactBi Wei

The Second Hospital of Hebei Medical University

15803210532@163.com+86 158 0321 0532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026